Transcriptional regulation of ADAMTS13

Summary

The metalloproteinase ADAMTS13 cleaves VWF multimers instantaneously when they are released from endothelial cells. Absent or manifestly diminished proteolytic activity of ADAMTS13 results in the appearance and accumulation of ultralarge VWF multimers (ULVWFM) in plasma, characterised by the manifestation of Thrombotic Thrombocytopenic Purpura (TTP). Despite congenital defects, infections and the actions of drugs such as cyclosporine A, doxycycline and corticosteroids apparently are involved in its development. To examine the possibility of transcriptional regulation of ADAMTS13 activity, we analyzed RNA levels in various cell culture systems and the response to known and assumed modulators of gene expression. We demonstrate the expression of ADAMTS13 in liver homogenates and a parenchyma liver cell culture system Hep3B, supporting the hypothesis that liver is an important source of plasma ADAMTS13, whereas there was no alteration in gene expression after stimulation of liver cells with proinflammatory stimuli such as endotoxin, TNF-α, IL-6, IL-1β as well as immuno-suppressive agents, such as cyclosporine A, a variety of steroids as well as doxycycline. Therefore, we analysed the ADAMTS13 gene for binding sites of transcription factors in silico and compared the data with those found in two sets of 24 genes considered either as differentially regulated by prototypic inflammatory regulation or as unvaried under various conditions. On the basis of these data, the promotor of ADAMTS13 features the characteristics of a gene, which remains unvaried under a variety of conditions. To our knowledge, the current data demonstrate for the first time, that an alteration in transcriptional activity is negligible in accounting for diminished proteolytic activity as observed under various experimental and, in particular, clinical conditions.

Keywords

ADAMTS13 - von Willebrand factor - gene expression

• References

• 1 Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424.
• 2 Dong JF, Moake JL, Nolasco L. et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-9.
• 3 Furlan M, Robles R, Solenthaler M. et al. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998; 91: 2839-46.
• 4 Furlan M, Robles R, Galbusera M. et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
• 5 Levy GG, Nichols WC, Lian EC. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-94.
• 6 Kokame K, Matsumoto M, Soejima K. et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 2002; 99: 11902-7.
• 7 Schneppenheim R, Budde U, Oyen F. et al. Von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood 2003; 101: 1845-50.
• 8 Bockmeyer CL, Brunkhorst FM, Claus RA. et al. Altered binding affinity and decreased proteolysis of von Willebrand-factor in SIRS and septic shock. Infection 2003; 31: 300.
• 9 Mannucci PM, Canciani MT, Forza I. et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98: 2730-5.
• 10 Mannucci PM, Parolari A, Canciani MT. et al. Opposite changes of ADAMTS-13 and von Willebrand factor after cardiac surgery. J Thromb Haemost 2005; 3: 397-9.
• 11 Arai S, Allan C, Streiff M. et al. Von Willebrand factor- cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy. Hematol J 2001; 2: 292-9.
• 12 Reiter RA, Knobl P, Varadi K. et al. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood 2003; 101: 946-8.
• 13 Mannucci PM, Capoferri C, Canciani MT. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol 2004; 126: 213-8.
• 14 Dlott JS, Danielson CF, Blue-Hnidy DE. et al. Druginduced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review. Therap Apher Dial 2004; 8: 102-11.
• 15 McCarthy LJ, Dlott JS, Orazi A. et al. Thrombotic thrombocytopenic purpura: yesterday, today, tomorrow. Therap Apher Dial 2004; 8: 80-6.
• 16 Fujikawa K, Suzuki H, McMullen B. et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98: 1662-6.
• 17 Gerritsen HE, Robles R, Lammle B. et al. Partial amino acid sequence of purified von Willebrand factorcleaving protease. Blood 2001; 98: 1654-61.
• 18 Zheng X, Chung D, Takayama TK. et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001; 276: 41059-63.
• 19 Suzuki M, Murata M, Matsubara Y. et al. Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. Biochem Biophys Res Commun 2004; 313: 212-6.
• 20 Soejima K, Mimura N, Hirashima M. et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor- cleaving protease?. J Biochem (Tokyo) 2001; 130: 475-80. Erratum in: J Biochem (Tokyo) 2001; 130: 719.
• 21 Lysek N, Kinscherf R, Claus R. et al. L-5-Hydroxytryptophan: antioxidant and anti-apoptotic principle of the intertidal sponge Hymeniacidon heliophila. Z Naturforsch (C) 2003; 58: 568-72.
• 22 Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol- chloroform extraction. Anal Biochem 1987; 162: 156-9.
• 23 Wachsmuth L, Bau B, Fan Z. et al. ADAMTS-1, a gene product of articular chondrocytes in vivo and in vitro, is downregulated by interleukin 1β. J Rheumatol 2004; 31: 315-20.
• 24 Wang WM, Lee S, Steiglitz BM. et al. Transforming growth factor-beta induces secretion of activated ADAMTS-2. A procollagen III N-proteinase. J Biol Chem 2003; 278: 19549-57.
• 25 Worley JR, Baugh MD, Hughes DA. et al. Metalloproteinase expression in PMA-stimulated THP-1 cells. Effects of peroxisome proliferator-activated receptorgamma (PPAR gamma) agonists and 9-cis-retinoic acid. J Biol Chem 2003; 278: 51340-6.
• 26 Quandt K, Frech K, Karas H. et al. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995; 23: 4878-84.
• 27 Klingenhoff A, Frech K, Quandt K. et al. Functional promoter modules can be detected by formal models independent of overall nucleotide sequence similarity. Bioinformatics 1999; 15: 180-6.
• 28 Cal S, Obaya AJ, Llamazares M. et al. Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene 2002; 283: 49-62.
• 29 Bohm M, Gerlach R, Beecken WD. et al. ADAMTS-13 activity in patients with brain and prostate tumors is mildly reduced, but not correlated to stage of malignancy and metastasis. Thromb Res 2003; 111: 33-7.
• 30 Plaimauer B, Zimmermann K, Volkel D. et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002; 100: 3626-32.
• 31 Williams SA, Vik DP. Characterization of the 5’ flanking region of the human complement factor H gene. Scand J Immunol 1997; 45: 7-15.
• 32 Knox-Macaulay HH, Adil SN, Ahmed EM. Acute thrombotic thrombocytopenic purpura following doxycycline treatment of Chlamydia pneumoniae infection in a patient with dermatomyositis. Clin Lab Haematol 2004; 26: 147-51.
• 33 Nothias JY, Majumder S, Kaneko KJ. et al. Regulation of gene expression at the beginning of mammalian development. J Biol Chem 1995; 270: 22077-80.